Emunkitug

**Semantic type:** Amino Acid, Peptide, or Protein|Immunologic Factor|Pharmacologic Substance

**Definition:** A humanized agonistic monoclonal antibody directed against tumor necrosis factor receptor 2 (TNFR2; tumor necrosis factor receptor superfamily member 1B; TNFRSF1B), with potential antineoplastic activity. Upon administration, emunkitug targets and binds to TNFR2 expressed on the surface of CD4+ T-cells, CD8+ T-cells and natural killer (NK) cells in the tumor micro-environment (TME), thereby activating CD4+ T-cells, CD8+ T-cells and NK cells. This may enhance T-cell- and NK cell- mediated immune responses against tumor cells. TNFR2, a member of the TNFR family of co-stimulatory molecules, plays an important role in T-cell co-stimulation.

**Synonyms:** - Anti-TNFR2 Agonist Antibody HFB200301 - Anti-TNFR2 Monoclonal Antibody HFB200301 - EMUNKITUG - HFB 200301 - HFB-200301 - HFB200301